Sign up to save your podcasts
Or
Share Pharma and Biotech Daily: RFK Jr. Accused of Spreading Mistrust, J&J Increases US Manufacturing, Fedegari Becomes One-Stop Solution Provider
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pharma and Biotech Daily: RFK Jr. Accused of Spreading Mistrust, J&J Increases US Manufacturing, Fedegari Becomes One-Stop Solution Provider
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. HHS employees have accused RFK Jr. of spreading public mistrust against the CDC after a shooting at their headquarters. They have asked him to stop spreading health misinformation, especially about vaccines and infectious diseases. In other news, Johnson & Johnson has added $2 billion to their US manufacturing commitment amid Trump's tariff threats. Regeneron's Eylea HD decisions have been delayed, and Stealth Biotherapeutics' rejected Barth drug is returning to the FDA for review. Fedegari is now a one-stop solution provider for the pharmaceutical industry, offering highly customized solutions for sterile drug production. Additionally, the American pharma industry is facing challenges with tariffs and policy changes. Several upcoming webinars and job opportunities in the pharmaceutical industry are also highlighted in the newsletter.
Support the show
View all episodes
By Pharma and BioTech News
3.3
1515 ratings
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. HHS employees have accused RFK Jr. of spreading public mistrust against the CDC after a shooting at their headquarters. They have asked him to stop spreading health misinformation, especially about vaccines and infectious diseases. In other news, Johnson & Johnson has added $2 billion to their US manufacturing commitment amid Trump's tariff threats. Regeneron's Eylea HD decisions have been delayed, and Stealth Biotherapeutics' rejected Barth drug is returning to the FDA for review. Fedegari is now a one-stop solution provider for the pharmaceutical industry, offering highly customized solutions for sterile drug production. Additionally, the American pharma industry is facing challenges with tariffs and policy changes. Several upcoming webinars and job opportunities in the pharmaceutical industry are also highlighted in the newsletter.
Support the show
More shows like Pharma and BioTech Daily
View all
Exchanges
952 Listeners
WSJ What’s News
4,334 Listeners
Bloomberg Intelligence
404 Listeners
Odd Lots
1,938 Listeners
WSJ Tech News Briefing
1,645 Listeners
The Readout Loud
321 Listeners
Wall Street Breakfast
1,046 Listeners
FT News Briefing
633 Listeners
Behind the Money
225 Listeners
Making Sense
61 Listeners
Thoughts on the Market
1,299 Listeners
The Journal.
6,066 Listeners
The World in Brief from The Economist
1,079 Listeners
Biotech Hangout
20 Listeners
The Markets
79 Listeners